GENB vs the Top Picks average
| Pillar | GENB | Book avg | Diff |
|---|---|---|---|
| Quality | 0.34 | 0.84 | -0.50 |
| Growth | 1.00 | 0.92 | +0.08 |
| Value | 0.02 | 0.75 | -0.73 |
Averaged across the 30 names in today's Top Picks (mean score 82.9). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Generate Biomedicines, Inc. (GENB): score, valuation & FAQ
Generate Biomedicines, Inc. (GENB) is a Biotechnology company that scores 25.7 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A) and D/E (B+), while P/S (D) and FCF (F) rate weaker.
Is GENB a good stock to buy?
Bull Rankings scores GENB 25.7 out of 100 on its quality-growth model, which is a weak reading. That is driven by Rev (A) and D/E (B+). A score is a quantitative screen of Generate Biomedicines, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does GENB score 25.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). GENB earns its highest marks on Rev (A) and D/E (B+), and is held back by P/S (D) and FCF (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is GENB overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for GENB — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in GENB?
Free cash flow is negative (-$246m) — capital raises or debt issuance likely required; dilution / leverage risk. P/S 73.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.